FDA, COPD and Dupixent
Pharma Stock Roundup: FDA Approves SNY's Dupixent for COPD & More
This week, the FDA granted approval to Sanofi SNY and Regeneron’s REGN blockbuster drug, Dupixent, for its sixth indication. The FDA also granted priority review designation to AstraZeneca’s AZN label expansion filings for two cancer drugs.
FDA Approves Dupilumab as Add-On for COPD
The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic obstructive pulmonary disease (COPD) is inadequately controlled with inhaler therapy, according to a press release from manufacturer Regeneron.
Sanofi, Regeneron look to seize major opportunity with Dupixent's COPD approval
After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with the progressive disease suddenly have two new options, with more likely o | Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD.
FDA Approves Dupixent Injections For People Struggling With COPD Symptoms
The FDA has approved Dupixent (dupilumab) as an add-on therapy for adults with poorly controlled COPD, especially those with elevated eosinophil levels. Clinical trials show that Dupixent reduces COPD exacerbations and improves symptoms when combined with inhaled medications,
FDA Approves Dupixent for Some Patients Struggling With COPD Symptoms
Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.
FDA approves first biologic treatment for COPD
The US Food and Drug Administration has approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic obstructive pulmonary disease (COPD). Dupixent is the first
Dupixent Gets FDA Approval for COPD
The label expansion provides a new option for the hundreds of thousands of Americans with inadequately controlled COPD.
FDA Approves Dupilumab as First Biologic Treatment for COPD
The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype to significantly help reduce exacerbations and improve lung function.
FDA greenlights Regeneron’s Dupixent for the treatment of COPD
With an approval based on two pivotal Phase III studies, Dupixent is now the first-ever biologic indicated for treating COPD.
Regeneron, Sanofi announce Dupixent approval in China for patients with COPD
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the National Medical Products Administration in China has approved Dupixent as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease characterized by raised blood eosinophils.
pulmonologyadvisor9h
Switching Between Inhalers, Both pMDI and DPI, Common in Asthma, COPD
Patients with asthma and COPD routinely switch from pressurized metered-dose inhalers (pMDIs) to dry powder inhalers (DPIs) and vice versa.
MedPage Today7d
First-Ever Biologic Approved for COPD
The FDA approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic obstructive pulmonary disease ...
Too Old to Operate2d
Cluster Analysis Reveals Heterogeneity in Symptom Burden Among Patients With COPD
Distinct patterns of symptom severity among patients with COPD sheds light on the heterogeneous nature of the patients’ ...
Renal & Urology News10h
N-Acetylcysteine Nebulizer for COPD is Effective, Safe for Phlegm Treatment
N-acetylcysteine (NAC) nebulizer therapy is effective and safe in the short-term (12 weeks) for reducing phlegm in COPD.
Older e-cigarette users face increased odds of respiratory issues, study finds
A study by doctoral student Adriana Eugene and Distinguished Professor Luisa N. Borrell found that older adults who use ...
Buy Rating for Verona Pharma as Ohtuvayre Shows Promise in COPD Treatment and Expansion Potential
Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram ...
Too Old to Operate3d
Managing Pneumothorax and Emphysema in COPD with Hyperthyroidism and Thyroid Storm
The following is a summary of “Losing Your Breath During the Storm: Spontaneous Pneumothorax and Subcutaneous Emphysema as a ...
The American Journal of Managed Care3d
Dupilumab Improves Lung Function, Type 2 Inflammation in COPD
Klaus Rabe, MD, PhD, chest physician and professor of medicine, University of Kiel, discusses improvements in lung function observed in patients enrolled in the BOREAS trial.